Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16577152 | 0.95 | SIGMAR1 (0.42) | SIGMAR1ALDH1A1TDP1CACNA1HSMN1; SMN2 | |
| SCHEMBL29466953 | 0.92 | SIGMAR1 (0.43) | SIGMAR1ALDH1A1TDP1CACNA1HSMN1; SMN2 | |
| SCHEMBL7130844 | 0.91 | ALDH1A1 (0.53) | SIGMAR1ALDH1A1TDP1CACNA1HSMN1; SMN2 | |
| SCHEMBL19748750 | 0.90 | SIGMAR1 (0.43) | SIGMAR1ALDH1A1TDP1CACNA1HSMN1; SMN2 | |
| SCHEMBL14642368 | 0.87 | ALDH1A1 (0.43) | SIGMAR1ALDH1A1TDP1CACNA1HSMN1; SMN2 | |
| SCHEMBL31165990 | 0.87 | ALDH1A1 (0.43) | SIGMAR1ALDH1A1TDP1CACNA1HSMN1; SMN2 | |
| SCHEMBL25917727 | 0.87 | SIGMAR1 (0.47) | SIGMAR1ALDH1A1TDP1CACNA1HSMN1; SMN2 | |
| SCHEMBL8328204 | 0.87 | CACNA1H (0.54) | SIGMAR1ALDH1A1TDP1CACNA1HSMN1; SMN2 | |
| SCHEMBL12644382 | 0.86 | CHRM2 (0.46) | SIGMAR1ALDH1A1TDP1CACNA1HSMN1; SMN2 | |
| SCHEMBL8183645 | 0.84 | SIGMAR1 (0.43) | SIGMAR1ALDH1A1TDP1CACNA1HSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576167-B2 | Gadolinium-based compound, method for producing same, and MRI contrast agent containing same | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2026-03-17 | — | — | US | disclosed |
| US-20250263393-A1 | FAP INHIBITORS | SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) | 2025-08-21 | — | — | US | disclosed |
| EP-4590664-A1 | INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND USE THEREOF | Shanghai Sinotau Biotech. Co., Ltd (CN) | 2025-07-30 | — | — | EP | disclosed |
| WO-2025055942-A1 | INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND USE THEREOF | SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) | 2025-03-20 | — | — | WO | disclosed |
| WO-2025055943-A1 | INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND USE THEREOF | SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) | 2025-03-20 | — | — | WO | disclosed |
| EP-4511367-A1 | FAP INHIBITORS | Shanghai Sinotau Biotech. Co., Ltd (CN) | 2025-02-26 | — | — | EP | disclosed |
| US-20240335569-A1 | FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF | 3 B Pharmaceuticals GmbH (DE) | 2024-10-10 | — | — | US | disclosed |
| US-20230381327-A1 | REACTIVE CONJUGATES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2023-11-30 | — | — | US | disclosed |
| US-20230381327-A1 | REACTIVE CONJUGATES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2023-11-30 | — | — | US | disclosed |
| WO-2023202655-A1 | FAP INHIBITORS | SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) | 2023-10-26 | — | — | WO | disclosed |
| US-20140170064-A1 | METHODS AND COMPOSITIONS FOR RADIOHALOGEN PROTEIN LABELING | GENENTECH, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140170064-A1 | METHODS AND COMPOSITIONS FOR RADIOHALOGEN PROTEIN LABELING | GENENTECH, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| EP-2604281-A1 | Clicked somatostatin conjugated analogs for biological applications | Centre National de la Recherche Scientifique (CNRS) (FR) | 2013-06-19 | — | — | EP | disclosed |
| US-20130034494-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS | 2013-02-07 | — | — | US | disclosed |
| US-20110177004-A1 | Version of FDG Detectable by Single-Photon Emission Computed Tomography | OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.) | 2011-07-21 | — | — | US | disclosed |
| US-20110177004-A1 | Version of FDG Detectable by Single-Photon Emission Computed Tomography | OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.) | 2011-07-21 | — | — | US | disclosed |
| WO-2010039609-A2 | A VERSION OF FDG DETECTABLE BY SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY | MALLINCKRODT INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| EP-1259532-B1 | BILE ACIDS CONJUGATES WITH METAL ION CHELATES AND THE USE THEREOF | BRACCO IMAGING SPA (IT) | 2005-05-04 | — | — | EP | disclosed |
| US-6803030-B2 | CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING | BRACCO IMAGING S.P.A. (IT) | 2004-10-12 | — | — | US | disclosed |
| US-20030113265-A1 | Bile acids conjugates with metal ion chelates and the use thereof | BRACCO IMAGING S.P.A. (IT) | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110177004-A1 | Version of FDG Detectable by Single-Photon Emission Computed Tomography | SLC2A1, SLC2A4, SLC2A3 | SIGMAR1 3174/4885ALDH1A1 959/4885TDP1 3943/4885 |
| US-20130034494-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | KLK3, FOLH1, PSMA1 | SIGMAR1 3926/4885ALDH1A1 2469/4885TDP1 3701/4885 |
| US-20140170064-A1 | METHODS AND COMPOSITIONS FOR RADIOHALOGEN PROTEIN LABELING | S100A6, HIRA, HDGFL3 | SIGMAR1 2651/4885ALDH1A1 3591/4885TDP1 2583/4885 |
| US-20240335569-A1 | FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF | FIBP, FGF2, FGFR2 | SIGMAR1 4356/4885ALDH1A1 2864/4885TDP1 4233/4885 |
| US-12576167-B2 | Gadolinium-based compound, method for producing same, and MRI contrast agent containing same | LGALS1, CLIC1, LGALS2 | SIGMAR1 2064/4885ALDH1A1 2510/4885TDP1 2991/4885 |
| US-20030113265-A1 | Bile acids conjugates with metal ion chelates and the use thereof | SLC10A2, SLC10A1, NR1H4 | SIGMAR1 1021/4885ALDH1A1 4431/4885TDP1 4559/4885 |
| US-20230381327-A1 | REACTIVE CONJUGATES | FCGR3B, FCGR1A, FCGR2A | SIGMAR1 4874/4885ALDH1A1 638/4885TDP1 4192/4885 |
| US-20250263393-A1 | FAP INHIBITORS | FAP, APC, FIBP | SIGMAR1 4872/4885ALDH1A1 1214/4885TDP1 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.